Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Plataforma tecnológica de estructura de proteínas de membrana para identificar nuevos compuestos farmacéuticos para proteínas diana de membrana

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOCH20170412001
Publicado:
24/04/2017
Caducidad:
24/04/2018
Resumen:
Una empresa suiza de biotecnología ofrece una plataforma tecnológica de identificación de nuevos compuestos farmacéuticos para proteínas diana de membrana. La plataforma combina diferentes tecnologías, como cristalización de proteínas, cristalografía de rayos X, criomicroscopía de electrones y caracterización de la interacción de ligandos con métodos computacionales y química medicinal para productos farmacéuticos. La empresa busca compañías farmacéuticas y biotecnológicas con el fin de establecer acuerdos de investigación, cooperación técnica o joint venture.

Details

Tittle:
Membrane protein structure technology platform for the identification of novel lead compounds for membrane protein targets
Summary:
A Swiss biotech company offers a technology platform for the identification of novel pharmaceutical lead compounds for membrane protein drug targets. The platform combines different technologies, e.g. protein crystallization, X-ray crystallography, cryo-electron microscopy and characterization of ligand interaction with computational methods with subsequent medicinal chemistry for pharmaceuticals. Research, technology cooperation or joint ventures with pharma and biotech companies is sought.
Description:
Membrane proteins represent some of the most promising drug targets. However, many membrane protein targets have failed to produce medicines due to a lack of high quality lead molecules. X-ray structure based lead generation methods and application of biophysical methods have been very difficult or impossible to apply due to a lack of high quality solubilized and purified membrane protein. In addition, crystallization of such proteins is very challenging.

The Swiss biotech SME is a lead compound discovery company focusing on membrane protein targets. It has access across all major cutting edge structure based drug design (SBDD) capabilities available at the Swiss Paul Scherrer Institute (PSI): Swiss Light Source (SLS); Synchrotron, Swiss Free Electron Laser (SwissFEL), serial crystallography and, in collaboration with a Swiss university, cryo-electron microscopy. This strong relationship between the Swiss SME and the facilities enables advances in structure determination of challenging membrane protein drug targets, e.g. G protein coupled receptors (GPCRs), ion channels and transporters.
The knowledge of the drug candidate and protein target 3d-structure, together with the full characterization of its interaction by biophysical binding and functional assays enables to generate novel and better lead molecules for future medicines.

The company is interested into technical or research cooperation with pharma or biotech companies with the aim to deliver novel drug-like lead molecules. The main area or interests are cancer therapeutics and antibiotics at the moment, but the technologies can be applied to any drug target.

Technology, research cooperation and join ventures in areas of method development for drug discovery (membrane protein science, assay development -Y- screening, biophysical methods, computational methods) are anticipated with academic and pharmaceutical industry partners.

Cooperation in the frame of European funding programs (e.g. Horizon 2020, Eurostar, IMI) is of interest.
Advantages and Innovations:
The Swiss SME enables the use of 3d structural information (focus on X-ray crystallography and electron microscopy) for the discovery and optimization of potential drug molecules. Consequently, they can design more specific and efficient drug-like molecules for therapeutic use. Structural information facilitates creation of novel molecules (scaffold hopping, fragment and focused library screening). Biophysical methods can be used to generate data for the optimization of binding affinity and residence time (association and dissociation rates kon, koff).
Stage of Development:
Already on the market
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
The specific area of activity of the partner:
The company is looking for partners in the biotech, pharma industry as well as academic institutes. The partner should be active in the field of drug discovery and development of technologies that facilitate such area.

The tasks to be performed by the partner sought:
Interest and capacity to complement our structure based lead compound discovery and optimization platform for membrane protein drug targets. This includes assay technologies, stabilization of proteins (nanodiscs), construct design for protein engineering. Compound screening technologies (including compound handling) with cellular, biochemical and biophysical assays.
Disease biology expertise especially in areas antibiotics and oncology.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002001 Bioquímica / biofísica
06001003 Citología, cancerología, oncología
06001015 Productos farmacéuticos / medicamentos
05001002 Química computacional y modelado
06001018 Virus, virología / antibióticos / bacteriología